


IA17 Rec'd PCT/PTO 22 DEC 2005


AMENDMENTS TO THE CLAIMS


1. (Original) An antiviral compound of Formula I




or pharmaceutically acceptable salts thereof,
 wherein,

R₁ =






R_a, R_b, R_c, R_d, R_e, R_f, R_h, R_k, R_L, R_m, R_n, R_o, R_p independently = hydrogen, amino, halo, C₁₋₅alkyl, C₁₋₅alkyloxy, hydroxy, aryl, substituted aryl, substituted amino, mono or dialkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino,




R_g, R_i independently = hydrogen, hydroxy, halo, or C_{1-5} alkyl;

R_j = hydrogen, amino, halo, C_{1-5} alkyl, C_{1-5} alkyloxy, hydroxy, aryl, substituted aryl, substituted amino, alkyl-substituted amino, cycloalkyl-substituted amino, aryl-substituted amino, PrS,



and wherein

when R_1 is , R_a and R_c are amino, and R_b is halo, R_2, R_3 or R_4 cannot be hydrogen, benzyl or substituted benzyl or BODIPY-FI;

when R_1 is $C_6H_5CH=CH$, R_2 is hydrogen and R_3 is phenyl, R_4 cannot be phenyl;

when R_1 is phenyl, R_2 is hydrogen, and R_3 is benzoyl, R_4 cannot be benzoyl;

when R_1 is phenyl, R_2 is substituted benzyl, R_3 is hydrogen and R_4 is hydrogen, R_n, R_o and R_p cannot all be hydrogen;

when R_1 is phenyl, R_3 is hydrogen and R_4 is hydrogen, R_2 cannot be benzyl or phenyl;

when R_1 is phenyl, R_2 is hydrogen, R_3 cannot be phenyl together with R_4 as benzoyl; and

when R₁ is phenyl, R₂ is hydrogen, R₃ and R₄ cannot both be benzyl.

2. (Original) A pharmaceutical composition comprising an antiviral compound according to claim 1 and optionally one or more pharmaceutical acceptable carriers or derivatives.
3. (Original) The pharmaceutical composition according to claim 3, further comprising one or more known antiviral compounds or molecules.
4. (Original) A method for reducing, retarding or otherwise inhibiting growth and/or replication of a virus comprising contacting a cell infected with said virus or exposed to said virus with a compound according to claim 1.
5. (Original) The method according to claim 4, wherein said virus is a Lentivirus.
6. (Original) The method according to claim 5, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
7. (Original) The method according to claim 6, wherein said compound is selected from the group consisting of :
 - (3-Chlorocinnamoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - 3-methylcinnamoylguanidine,
 - 2-methylcinnamoylguanidine,
 - 2,3-dimethylcinnamoylguanidine,
 - Cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 2,6-dichlorocinnamoylguanidine,

4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,

Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

8. (Original) The method according to claim 6, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.
9. (Original) The method according to any one of claims 6 to 8, wherein said HIV is HIV-1.
10. (Original) The method according to claim 4 wherein said virus is a Coronavirus.

11. (Original) The method according to claim 10, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
12. (Original) The method according to claim 11, wherein said compound is selected from the group consisting of

2,3-difluorocinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
(3-Chlorocinnamoyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2,5-dimethylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-isopropylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
6-methoxy-2-naphthoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenazamil HCl
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,

2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

13. (Original) The method according to claim 11, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-naphthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.
14. (Original) The method according to claim 10, wherein said Coronavirus is human Coronavirus 229E.
15. (Original) The method according to claim 14, wherein said compound is selected from the group consisting of
 - 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - 3-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 2,3-difluorocinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 2-phenylcinnamoylguanidine,
 - 3-phenylcinnamoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - 1-naphthoylguanidine,
 - 5-(4-fluorophenyl)amiloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - (3-Methoxycinnamoyl)guanidine,

5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,

(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-Pyrazinecarboxamide,
N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy-HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phenyl-2-Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

16. (Original) The method according to claim 14, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
3-(2-naphthyl)acryloylguanidine,
2,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,

4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-naphthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-naphthyl)acetoylguanidine,

(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-naphthyl)acetoxyguanidine and
N,N'-bis(3phenylpropanoyl)-N''-
Phenylguanidine.

17. (Original) The method according to claim 10, wherein said Coronavirus is human Coronavirus OC43.
18. (Original) The method according to claim 17, wherein said compound is selected from the group consisting of
3-methylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.
19. (Original) The method according to claim 10, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).
20. (Original) The method according to claim 19, wherein said compound is selected from the group consisting of
5-(N,N-hexamethylene)amiloride,
6-methoxy-2-naphthoylguanidine,

Cinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
3-methylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine and
2-(2-naphthyl)acetoyleguanidine.

21. (Original) The method according to claim 10, wherein said Coronavirus is bovine Coronavirus (BCV).
22. (Original) The method according to claim 21, wherein said compound is selected from the group consisting of
(3-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-hexamethylene)amiloride,
trans-3-(1-naphthyl)acryloylguanidine,
Cinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine and
4-phenylbenzoylguanidine.
23. (Original) The method according to claim 10, wherein said Coronavirus is any one of the known coronavirus isolates listed in Table 1.
24. (Original) The method according to claim 23, wherein said compound is selected from the group consisting of
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
25. (Original) The method according to claim 4, wherein said virus is the Hepatitis C virus.

26. (Original) The method according to claim 25, wherein said compound is selected from the group consisting of

2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,

(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

27. (Original) The method according to claim 4, wherein said virus is Equine Arteritis virus.
28. (Original) The method according to claim 27, wherein said compound is selected from the group consisting of
5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1-yl)cinnamoylguanidine.
29. (Currently amended) A method according to claim 4 ~~any one of claims 4 to 28~~, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
30. (Original) A method for preventing the infection of a cell exposed to a virus comprising contacting said cell with a compound according to claim 1.
31. (Original) The method according to claim 30, wherein said virus is a Lentivirus.
32. (Original) The method according to claim 31, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
33. (Original) The method according to claim 32, wherein said compound is selected from the group consisting of
(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,

3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,

N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

34. (Original) The method according to claim 32, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.
35. (Currently amended) The method according to claim 32 ~~any one of claims 32 to 34~~, wherein said HIV is HIV-1.

36. (Original) The method according to claim 30 wherein said virus is a Coronavirus.
37. (Original) The method according to claim 36, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
38. (Original) The method according to claim 37, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 3,4,5-trimethoxycinnamoylguanidine,
 - 5-tert-butylamino-amiloride,
 - 3-t-butylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 6-Iodoamiloride,
 - 3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - (4-Hydroxycinnamoyl)guanidine,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,

(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy –HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[[4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,

N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

39. (Original)The method according to claim 37, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-naphthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.
40. (Original)The method according to claim 36, wherein said Coronavirus is human Coronavirus 229E
41. (Original)The method according to claim 40, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - 3-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 2,3-difluorocinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 2-phenylcinnamoylguanidine,
 - 3-phenylcinnamoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - 1-naphthoylguanidine,
 - 5-(4-fluorophenyl)amiloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,

2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,

N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
Pyrazinecarboxamide,
N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy-HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phenyl-2-
Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

42. (Original) The method according to claim 40, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,

trans-3-(1-naphthyl)acryloylguanidine,
3-(2-naphthyl)acryloylguanidine,
2,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-naphthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,

2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-naphthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-naphthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N''-
Phenylguanidine.

43. (Original) The method according to claim 36, wherein said Coronavirus is human Coronavirus OC43.
44. (Original) The method according to claim 43, wherein said compound is selected from the group consisting of
3-methylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.
45. (Original) The method according to claim 36, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).

46. (Original) The method according to claim 45, wherein said compound is selected from the group consisting of
- 5-(N,N-hexamethylene)amiloride,
 - 6-methoxy-2-naphthoylguanidine,
 - Cinnamoylguanidine,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,
 - 3-methylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (trans-2-Phenylcyclopropanecarbonyl)guanidine,
 - trans-3-(1-naphthyl)acryloylguanidine and
 - 2-(2-naphthyl)acetoylguanidine.
47. (Original) The method according to claim 36, wherein said Coronavirus is bovine Coronavirus (BCV).
48. (Original) The method according to claim 47, wherein said compound is selected from the group consisting of
- (3-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - Cinnamoylguanidine,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - 2-(2-naphthyl)acetoylguanidine,
 - (trans-2-Phenylcyclopropanecarbonyl)guanidine,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine and
 - 4-phenylbenzoylguanidine.
49. (Original) The method according to claim 36, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
50. (Original) The method according to claim 49, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,

51. (Original) The method according to claim 30, wherein said virus is the Hepatitis C virus.
52. (Original) The method according to claim 51, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
 - 2,4,6-trimethylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - 4-methylcinnamoylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 1-naphthoylguanidine,
 - 3-t-butylcinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - N-(cinnamoyl)-N'-phenylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - Benzamil hydrochloride,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,
 - N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 2'4 DichloroBenazamil HCl,
 - 5-tert-butylamino-amiloride,

5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and

[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

53. (Original) The method according to claim 30, wherein said virus is the Equine Arteritis virus.
54. (Original) The method according to claim 53, wherein said compound is selected from the group consisting of
5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1-yl)cinnamoylguanidine.
55. (Currently amended) The method according to claim 30 ~~any one of claims 30 to 54~~, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
56. (Original) A method for the therapeutic or prophylactic treatment of a subject infected with or exposed to a virus, comprising the administration of a compound according to claim 1 to a subject in need of said treatment.
57. (Original) The method according to claim 56, wherein said virus is a Lentivirus.
58. (Original) The method according to claim 57, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
59. (Original) The method according to claim 58, wherein said compound is selected from the group consisting of
(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,

2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoylguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,

2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N"-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

60. (Original) The methods according to claim 58, wherein said compound is selected from the group consisting of 4-phenylbenzoylguanidine, (3-bromocinnamoyl)guanidine, 3-(trifluoromethyl)cinnamoylguanidine, 5-(N,N-hexamethylene)amiloride, and (5-Phenyl-penta-2,4-dienoyl)guanidine.

61. (Currently amended) The method according to claim 58 ~~any one of claims 58 to 60~~, wherein said HIV is HIV-1.
62. (Original) The method according to claim 56 wherein said virus is a Coronavirus.
63. (Original) The method according to claim 62, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
64. (Original) The method according to claim 63, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 3,4,5-trimethoxycinnamoylguanidine,
 - 5-tert-butylamino-amiloride,
 - 3-t-butylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 6-Iodoamiloride,

3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,

1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

65. (Original) The method according to claim 63, wherein said compound is selected from the group consisting of cinnamoylguanidine, trans-3-(1-naphthyl)acryloylguanidine, and 6-methoxy-2-naphthoylguanidine.
66. (Original) The method according to claim 62, wherein said Coronavirus is human Coronavirus 229E.
67. (Original) The method according to claim 66, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - 3-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 2,3-difluorocinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 2-phenylcinnamoylguanidine,
 - 3-phenylcinnamoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - 1-naphthoylguanidine,
 - 5-(4-fluorophenyl)amiloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,

2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,

N-(3-phenylpropanoyl)-N'-phenylguanidine,

5-(2'-bromophenyl)penta-2,4-
dienoylguanidine,
(4-Bromocinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine,
N-Benzoyl-N'-cinnamoylguanidine,
4-phenylbenzoylguanidine,
trans-3-Furanacryoylguanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
Pyrazinecarboxamide,
N-(cinnamoyl)-N'phenylguanidine,
Cinnamoylguanidine,
3-methoxy-amiloride,
(3-phenylpropanoyl)guanidine,
3-methoxy -HMA,
Benzyoylguanidine,
N-amidino-3,5-diamino-6-phenyl-2-
Pyrazinecarboxamide,
(Quinoline-2-carbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine and
(Phenylacetyl)guanidine.

68. (Original) The method according to claim 66, wherein said compound is selected from the group consisting of

2-t-butylcinnamoylguanidine,
4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2-phenylcinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,

trans-3-(1-naphthyl)acryloylguanidine,
3-(2-naphthyl)acryloylguanidine,
2,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
4-methylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(a-Methylcinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-t-butylcinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
3-methylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(2-Bromocinnamoyl)guanidine,
3-ethoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-
Phenylguanidine,
2,4,6-trimethylcinnamoylguanidine,
2-methylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)-
guanidine,
(4-Phenoxybenzoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
Cinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-
Dicarboxamide,
2,3-dimethylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
2,3-difluorocinnamoylguanidine,
1-naphthoylguanidine,
6-methoxy-2-naphthoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-ethoxycinnamoylguanidine,
2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,

2-(trifluoromethyl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
(4-Hydroxycinnamoyl)guanidine,
5-(4-fluorophenyl)amiloride,
2-(1-naphthyl)acetoylguanidine,
(2-Furanacryloyl)guanidine,
N-Cinnamoyl-N',N'-dimethylguanidine,
2-(2-naphthyl)acetoylguanidine and
N,N'-bis(3phenylpropanoyl)-N''-
Phenylguanidine.

69. (Original) The method according to claim 62, wherein said Coronavirus is human Coronavirus OC43.

70. (Original) The method according to claim 69, wherein said compound is selected from the group consisting of

3-methylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
4-isopropylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
2,4-dichlorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
(4-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-(trifluoromethoxy)cinnamoylguanidine and
2-t-butylcinnamoylguanidine.

71. (Original) The method according to claim 62, wherein said Coronavirus is porcine respiratory Coronavirus (PRCV).

72. (Original) The method according to claim 71, wherein said compound is selected from the group consisting of
- 5-(N,N-hexamethylene)amiloride,
 - 6-methoxy-2-naphthoylguanidine,
 - Cinnamoylguanidine,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,
 - 3-methylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (trans-2-Phenylcyclopropanecarbonyl)guanidine,
 - trans-3-(1-naphthyl)acryloylguanidine and
 - 2-(2-naphthyl)acetoyleguanidine.
73. (Original) The method according to claim 62, wherein said Coronavirus is bovine Coronvirus (BCV).
74. (Original) The method according to claim 73, wherein said compound is selected from the group consisting of
- (3-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - Cinnamoylguanidine,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - 2-(2-naphthyl)acetoyleguanidine,
 - (trans-2-Phenylcyclopropanecarbonyl)guanidine,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine and
 - 4-phenylbenzoylguanidine.
75. (Original) The method according to claim 62, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
76. (Original) The method according to claim 75, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,

77. (Original) The method according to claim 56, wherein said virus is the Hepatitis C virus.
78. (Original) The method according to claim 77, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
 - 2,4,6-trimethylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - 4-methylcinnamoylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 1-naphthoylguanidine,
 - 3-t-butylcinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - N-(cinnamoyl)-N'-phenylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - Benzamil hydrochloride,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,
 - N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 2'4 DichloroBenazamil HCl,
 - 5-tert-butylamino-amiloride,

5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and

[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

79. (Original) The method according to claim 56, wherein said virus is the Equine Arteritis virus.
80. (Original) The method according to claim 79, wherein said compound is selected from the group consisting of
5-(N,N-hexamethylene)amiloride,
(3-Bromocinnamoyl)guanidine,
trans-3-(1-naphthyl)acryloylguanidine,
2-t-butylcinnamoylguanidine and
2-(cyclohex-1-en-1-yl)cinnamoylguanidine.
81. (Currently amended) The method according to claim 56 ~~any one of claims 56 to 80~~, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
82. (Original) A method of down regulating a membrane ion channel functional activity in a cell infected with a virus, comprising contacting said cell with a compound according to claim 1.
83. (Original) The method according to claim 82, wherein said virus is a Lentivirus.
84. (Original) The method according to claim 83, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
85. (Original) The method according to claim 84, wherein said membrane ion channel is the HIV Vpu membrane ion channel.
86. (Original) The method according to claim 85, wherein said compound is selected from the group consisting of
(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,

(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,

2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'-phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

87. (Currently amended) The method according to claim 84 ~~any one of claims 84 to 86~~,
wherein said HIV is HIV-1.

88. (Original) The method according to claim 82, wherein said virus is a Coronavirus.
89. (Original) The method according to claim 88, wherein said membrane ion channel is the Coronavirus E protein.
90. (Original) The method according to claim 89, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
91. (Original) The method according to claim 90, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 3,4,5-trimethoxycinnamoylguanidine,
 - 5-tert-butylamino-amiloride,
 - 3-t-butylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - 2-t-butylcinnamoylguanidine,

2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,

N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

92. (Original) The method according to claim 90, wherein said Coronavirus is human Coronavirus 229E.
93. (Original) The method according to claim 92, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - 3-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 2,3-difluorocinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 2-phenylcinnamoylguanidine,
 - 3-phenylcinnamoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(N,N-hexamethylene)amiloride,
 - 1-naphthoylguanidine,
 - 5-(4-fluorophenyl)amiloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,

6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(α -Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

94. (Original) The method according to claim 89, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
95. (Original) The method according to claim 94, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
96. (Original) The method according to claim 82, wherein said virus is the Hepatitis C virus.
97. (Original) The method according to claim 96, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.
98. (Original) The method according to claim 97, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
 - 2,4,6-trimethylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,

4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,

3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

99. (Currently amended) The method according to claim 82 ~~any one of claims 82 to 98~~, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
100. (Original) A method of reducing, retarding or otherwise inhibiting growth and/or replication of a virus that has infected a cell, said method comprising contacting said infected cell with a compound according to claim 1, wherein said compound down regulates functional activity of a membrane ion channel derived from said virus and expressed in said infected cell.
101. (Original) The method according to claim 100, wherein said virus is a Lentivirus.
102. (Original) The method according to claim 101, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).

103. (Original) The method according to claim 102, wherein said membrane ion channel is the HIV Vpu membrane ion channel.

104. (Original) The method according to claim 103, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,

5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'-phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,

(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

105. (Currently amended) The method according to claim 102 ~~any one of claims 102 to 104~~, wherein said HIV is HIV-1.
106. (Original) The method according to claim 100, wherein said virus is a Coronavirus.
107. (Original) The method according to claim 106, wherein said membrane ion channel is the Coronavirus E protein.
108. (Original) The method according to claim 107, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
109. (Original) The method according to claim 108, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,

3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy-HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoylguanidine,
Cinnamoylguanidine,

(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(α -Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

110. (Original) The method according to claim 107, wherein said Coronavirus is human Coronavirus 229E.

111. (Original) The method according to claim 110, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,

(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,

2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

112. (Original) The method according to claim 107, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
113. (Original) The method according to claim 112, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
114. (Original) The method according to claim 100, wherein said virus is the Hepatitis C virus.
115. (Original) The method according to claim 114, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.
116. (Original) The method according to claim 115, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,

(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,

2-(1-naphthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamolyguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

117. (Currently amended) The method according to claim 100 ~~any one of claims 100 to 116~~, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
118. (Original) A method of reducing, retarding or otherwise inhibiting growth and/or replication of a virus that has infected a cell in a mammal, said method comprising administering to said mammal a compound according claim 1, wherein said

compound down regulates functional activity of a membrane ion channel expressed in said infected cell.

119. (Original) The method according to claim 118, wherein said virus is a Lentivirus.
120. (Original) The method according to claim 119, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
121. (Original) The method according to claim 120, wherein said compound is selected from the group consisting of
- (3-Chlorocinnamoyl)guanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - 3-methylcinnamoylguanidine,
 - 2-methylcinnamoylguanidine,
 - 2,3-dimethylcinnamoylguanidine,
 - Cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - (4-Chlorocinnamoyl)guanidine,,
 - 2-naphthoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - 3-phenylcinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - (4-Methoxycinnamoyl)guanidine,

2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'-phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamil methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamoylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,

(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryloylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy-HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and
1-bromo-2-naphthoylguanidine.

122. (Currently amended) The method according to claim 118 ~~any one of claims 118 to 121~~, wherein said membrane ion channel is the HIV Vpu membrane ion channel.
123. (Currently amended) The method according to claim 120 ~~any one of claims 120 to 122~~, wherein said HIV is HIV-1.
124. (Original) The method according to claim 118, wherein said virus is a Coronavirus.
125. (Original) The method according to claim 124, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
126. (Original) The method according to claim 125, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,

3-phenylcinnamoylguanidine,
(2-Chlorocinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
4-phenylcinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
cinnamoylguanidine hydrochloride,
4-ethoxycinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,

trans-3-Furanacryloylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoxyguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

127. (Currently amended) The method according to claim 124 ~~any one of claim 124 or 126~~, wherein said membrane ion channel is the Coronavirus E protein.
128. (Original) The method according to claim 124, wherein said Coronavirus is human Coronavirus 229E.
129. (Original) The method according to claim 128, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - 3-t-butylcinnamoylguanidine,

2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,

2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

130. (Currently amended) The method according to claim 128 ~~any one of claims 128 or 129~~, wherein said membrane ion channel is the Coronavirus E protein.
131. (Original) The method according to claim 124, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
132. (Original)The method according to claim 131, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
133. (Original)The method according to claim 131 or claim 132, wherein said membrane ion channel is the Coronavirus E protein.

134. (Original) The method according to claim 118, wherein said virus is the Hepatitis C virus.
135. (Original) The method according to claim 134, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
 - 2,4,6-trimethylcinnamoylguanidine,
 - 5-bromo-2-fluorocinnamoylguanidine,
 - (4-Bromocinnamoyl)guanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - (4-Chlorocinnamoyl)guanidine,
 - (2-Bromocinnamoyl)guanidine,
 - 2,6-dichlorocinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 2-(trifluoromethyl)cinnamoylguanidine,
 - (4-Phenoxybenzoyl)guanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 2-t-butylcinnamoylguanidine,
 - 2-ethylcinnamoylguanidine,
 - 4-methylcinnamoylguanidine,
 - 5-bromo-2-methoxycinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 2-cyclohexylcinnamoylguanidine,
 - 1-naphthoylguanidine,
 - 3-t-butylcinnamoylguanidine,
 - 4-phenylbenzoylguanidine,
 - (5-Phenyl-penta-2,4-dienoyl)guanidine,
 - N-(cinnamoyl)-N'-phenylguanidine,
 - 3-isopropylcinnamoylguanidine hydrochloride,
 - Benzamil hydrochloride,
 - N-(3-phenylpropanoyl)-N'-phenylguanidine,
 - N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 2'4 DichloroBenazamil HCl,
 - 5-tert-butylamino-amiloride,

5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(α-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,
3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and

[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine.

136. (Original) The method according to claim 135, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.
137. (Currently amended) The method according to claim 118 ~~any one of claims 118 to 130~~, wherein said mammal is a primate.
138. (Currently amended) The method according to claim 134 ~~any one of claims 134 to 136~~, wherein said mammal is a primate.
139. (Original) The method according to claim 137 or claim 138, wherein said primate is human.
140. (Currently amended) The method according to claim 118 ~~any one of claims 118 to 139~~, wherein said compound is provided as a pharmaceutical composition according to claim 2 or claim 3.
141. (Original) A method for the therapeutic or prophylactic treatment of a subject infected with or exposed to a virus comprising administering to said subject a compound according to claim 1, wherein said compound down-regulates functional activity of a membrane ion channel derived from said virus.
142. (Original) The method according to claim 141, wherein said virus is a Lentivirus.
143. (Original) The method according to claim 142, wherein said Lentivirus is Human Immunodeficiency Virus (HIV).
144. (Original) The method according to claim 143, wherein said membrane ion channel is the HIV Vpu membrane ion channel.

145. (Original) The method according to claim 144, wherein said compound is selected from the group consisting of

(3-Chlorocinnamoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
3-(trifluoromethyl)cinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3-dimethylcinnamoylguanidine,
Cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
3,4-dichlorocinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
4-phenylbenzoylguanidine,
2-ethylcinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,,
2-naphthoylguanidine,
2,5-dimethylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
3-phenylcinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N"-phenylguanidine,
2-ethoxycinnamoylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
(4-Methoxycinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
4-methylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
2-phenylcinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
3-t-butylcinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
3-fluorocinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-ethoxycinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,

(2-Methoxycinnamoyl)guanidine,
2'4 DichloroBenazamil HCl,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2,3-difluorocinnamoylguanidine,
(3-Methoxycinnamoyl)guanidine,
4-isopropylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-(2-naphthyl)acetoyleguanidine,
(4-Hydroxycinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
(2-Furanacryloyl)guanidine,
Phenamyl methanesulfonate salt ,
Benzamil hydrochloride,
(3-Nitrocinnamoyl)guanidine,
Benzyoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2-cyclohexylcinnamoylguanidine,
4-ethoxycinnamoylguanidine,
2,4-dichlorocinnamolyguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
N-amidino-3-amino-5-hexamethyleneimino-6-phenyl-
2-pyrazinecarboxamide,
(a-Methylcinnamoyl)guanidine,
cinnamoylguanidine hydrochloride,
[(4-Chlorophenoxy-acetyl]guanidine,
N-amidino-3-amino-5-phenyl-6-chloro-2-
pyrazinecarboxamide,
5-(4-fluorophenyl)amiloride,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
trans-3-Furanacryoylguanidine,
1-naphthoylguanidine,
5-tert-butylamino-amiloride,
3-methoxy -HMA,
(3-phenylpropanoyl)guanidine,
4-t-butylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
N,N'-Bis(3-phenylpropanoyl)guanidine,
N-Benzoyl-N'-cinnamoylguanidine and

1-bromo-2-naphthoylguanidine.

146. (Currently amended) The method according to claim 143 ~~any one of claims 143 to 145~~, wherein said HIV is HIV-1.
147. (Original) The method according to claim 141, wherein said virus is a Coronavirus.
148. (Original) The method according to claim 147, wherein said membrane ion channel is the Coronavirus E protein.
149. (Original) The method according to claim 148, wherein said Coronavirus is the Severe Acute Respiratory Syndrome virus (SARS).
150. (Original) The method according to claim 149, wherein said compound is selected from the group consisting of
- 2,3-difluorocinnamoylguanidine,
 - 3,4-dichlorocinnamoylguanidine,
 - 4-t-butylcinnamoylguanidine,
 - 3-(2-naphthyl)acryloylguanidine,
 - (3-Chlorocinnamoyl)guanidine,
 - 3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
 - 2,5-dimethylcinnamoylguanidine,
 - trans-3-(1-naphthyl)acryloylguanidine,
 - 4-isopropylcinnamoylguanidine,
 - (3-Bromocinnamoyl)guanidine,
 - 6-methoxy-2-naphthoylguanidine,
 - 5-(N-Methyl-N-isobutyl)amiloride,
 - 3-phenylcinnamoylguanidine,
 - (2-Chlorocinnamoyl)guanidine,
 - 2'4 DichloroBenazamil HCl,
 - 4-phenylcinnamoylguanidine,
 - 4-(trifluoromethyl)cinnamoylguanidine,
 - 3-(trifluoromethoxy)cinnamoylguanidine,
 - 3-(trifluoromethyl)cinnamoylguanidine,
 - 2-ethoxycinnamoylguanidine,
 - cinnamoylguanidine hydrochloride,
 - 4-ethoxycinnamoylguanidine,
 - (2-Bromocinnamoyl)guanidine,

2,6-dichlorocinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
5-tert-butylamino-amiloride,
3-t-butylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Chlorocinnamoyl)guanidine,
2-t-butylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
6-Iodoamiloride,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
(4-Hydroxycinnamoyl)guanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
(3-Nitrocinnamoyl)guanidine,
3-fluorocinnamoylguanidine,
2-(1-naphthyl)acetoyleguanidine,
2-ethylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
2-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
2-(trifluoromethyl)cinnamoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
1-naphthoylguanidine,
Benzamil hydrochloride,
3-methoxy -HMA,
4-methylcinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-(methylenedioxy)cinnamoylguanidine,
5-(N,N-hexamethylene)amiloride,
N-(cinnamoyl)-N'phenylguanidine,
5-(N-Ethyl-N-isopropyl)amiloride,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
(4-Methoxycinnamoyl)guanidine,
(2-Furanacryloyl)guanidine,
(3-phenylpropanoyl)guanidine,
2-(2-naphthyl)acetoyleguanidine,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
4-phenylbenzoylguanidine,
2,4-dichlorocinnamolyguanidine,
(3-Methoxycinnamoyl)guanidine,

2-fluorocinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
6-bromo-2-naphthoylguanidine,
1-bromo-2-naphthoylguanidine,
2-chloro-6-fluorocinnamoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
Phenamil methanesulfonate salt ,
N-Benzoyl-N'-cinnamoylguanidine and
N-(2-naphthoyl)-N'-phenylguanidine.

151. (Original) The method according to claim 148, wherein said Coronavirus is human Coronavirus 229E.

152. (Original) The method according to claim 151, wherein said compound is selected from the group consisting of

4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
3-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
2,3-difluorocinnamoylguanidine,
3-(2-naphthyl)acryloylguanidine,
2-phenylcinnamoylguanidine,
3-phenylcinnamoylguanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
4-phenylbenzoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
4-(trifluoromethyl)cinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,

5-(N,N-hexamethylene)amiloride,
1-naphthoylguanidine,
5-(4-fluorophenyl)amiloride,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
2-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(4-Chlorocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
5-bromo-2-fluorocinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
Cinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
(a-Methylcinnamoyl)guanidine,
4-phenylcinnamoylguanidine,
2,6-dichlorocinnamoylguanidine,
(2-Bromocinnamoyl)guanidine,
2,4,6-trimethylcinnamoylguanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
2-(1-naphthyl)acetoylguanidine,
2-ethylcinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
2-ethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
2-methylcinnamoylguanidine,
3-fluorocinnamoylguanidine,
cinnamoylguanidine hydrochloride,
2,3-dimethylcinnamoylguanidine,
2-fluorocinnamoylguanidine,
4-fluorocinnamoylguanidine,
3,4-difluorocinnamoylguanidine,
5-tert-butylamino-amiloride,
2-naphthoylguanidine,
N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N,N'-Bis(3-phenylpropanoyl)guanidine,
4-methylcinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
3-ethoxycinnamoylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
(4-Methoxycinnamoyl)guanidine,

(2-Chlorocinnamoyl)guanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
2-(2-naphthyl)acetoylguanidine and
N-(3-phenylpropanoyl)-N'-phenylguanidine.

153. (Original) The method according to claim 148, wherein said Coronavirus is any one of the known Coronavirus isolates listed in Table 1.
154. (Original) The method according to claim 153, wherein said compound is selected from the group consisting of
- 4-isopropylcinnamoylguanidine,
3,4-dichlorocinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
4-t-butylcinnamoylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
155. (Original) The method according to claim 141, wherein said virus is the Hepatitis C virus.
156. (Original) The method according to claim 155, wherein said membrane ion channel is the Hepatitis C virus p7 membrane ion channel.
157. (Original) The method according to claim 156, wherein said compound is selected from the group consisting of
- 2,3-dimethylcinnamoylguanidine,
2,4,6-trimethylcinnamoylguanidine,
5-bromo-2-fluorocinnamoylguanidine,
(4-Bromocinnamoyl)guanidine,
2,5-dimethylcinnamoylguanidine,
3-(trifluoromethyl)cinnamoylguanidine,
4-(trifluoromethyl)cinnamoylguanidine,
6-methoxy-2-naphthoylguanidine,
(2-Chlorocinnamoyl)guanidine,
(4-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
2,6-dichlorocinnamoylguanidine,
(3-Bromocinnamoyl)guanidine,

(3-Chlorocinnamoyl)guanidine,
2-(trifluoromethyl)cinnamoylguanidine,
(4-Phenoxybenzoyl)guanidine,
3,4-dichlorocinnamoylguanidine,
4-isopropylcinnamoylguanidine,
trans-3-(1-naphthyl)acryloylguanidine,
4-t-butylcinnamoylguanidine,
2-t-butylcinnamoylguanidine,
2-ethylcinnamoylguanidine,
4-methylcinnamoylguanidine,
5-bromo-2-methoxycinnamoylguanidine,
3-(trifluoromethoxy)cinnamoylguanidine,
2-cyclohexylcinnamoylguanidine,
1-naphthoylguanidine,
3-t-butylcinnamoylguanidine,
4-phenylbenzoylguanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
N-(cinnamoyl)-N'-phenylguanidine,
3-isopropylcinnamoylguanidine hydrochloride,
Benzamil hydrochloride,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
3-(2-naphthyl)acryloylguanidine,
5-(N-Methyl-N-isobutyl)amiloride,
2'4 DichloroBenazamil HCl,
5-tert-butylamino-amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
(4-Methoxycinnamoyl)guanidine,
4-fluorocinnamoylguanidine,
(3-Nitrocinnamoyl)guanidine,
4-ethoxycinnamoylguanidine,
(4-Hydroxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
3-ethoxycinnamoylguanidine,
2,3,5,6,-tetramethylcinnamoylguanidine,
4-phenylcinnamoylguanidine,
trans-3-Furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(2-Furanacryloyl)guanidine,
3-(cyclohex-1-en-1-yl)cinnamoylguanidine,
cinnamoylguanidine hydrochloride,
5-(N,N-hexamethylene)amiloride,
2,3-difluorocinnamoylguanidine,
2-(1-naphthyl)acetoylguanidine,
(a-Methylcinnamoyl)guanidine,
(2-Nitrocinnamoyl)guanidine,
6-Iodoamiloride,

3,4-(methylenedioxy)cinnamoylguanidine,
2-ethoxycinnamoylguanidine,
Cinnamoylguanidine,
2-phenylcinnamoylguanidine,
2-(cyclohex-1-en-1-yl)cinnamoylguanidine,
2-naphthoylguanidine,
3-phenylcinnamoylguanidine,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(4-fluorophenyl)amiloride,
(3-Methoxycinnamoyl)guanidine,
2-fluorocinnamoylguanidine,
5-(3'-bromophenyl)penta-2,4-dienoylguanidine,
[(4-Chlorophenoxy-acetyl]guanidine,
(3-phenylpropanoyl)guanidine,
2-chloro-6-fluorocinnamoylguanidine,
3-fluorocinnamoylguanidine,
2-methylcinnamoylguanidine,
(2-Methoxycinnamoyl)guanidine,
1-bromo-2-naphthoylguanidine,
3,4,5-trimethoxycinnamoylguanidine,
3-methylcinnamoylguanidine,
3-(trans-hept-1-en-1-yl)cinnamoylguanidine,
Phenamil methanesulfonate salt ,
2,4-dichlorocinnamoylguanidine,
(4-Nitrocinnamoyl)guanidine,
3,4-difluorocinnamoylguanidine and
[(E)-3-(4-Dimethylaminophenyl)-2-
methylacryloyl]guanidine.

158. (Currently amended) The method according to claim 141 ~~any one of claims 141 to 152~~, wherein said mammal is a primate.
159. (Currently amended) The method according to claim 155 ~~any one of claims 155 to 157~~, wherein said mammal is a primate.
160. (Original) The method according to claim 158 or claim 159, wherein said primate is human.
161. (Original) An antiviral compound selected from the group consisting of
N-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-N'-phenyl-guanidine,
5-(N-methyl-N-guanidinocarbonyl-methyl)amiloride,

5-(N-Methyl-N-isobutyl)amiloride,
5-(N-Ethyl-N-isopropyl)amiloride,
5-(N,N-Dimethyl)amiloride hydrochloride,
5-(N,N-hexamethylene)amiloride,
5-(N,N-Diethyl)amiloride hydrochloride,
3-hydroxy-5-hexamethyleneimino-amiloride,
5-(4-fluorophenyl)amiloride,
5-tert-butylamino-amiloride,
N-amidino-3-amino-5-phenyl-6-chloro-2-pyrazinecarboxamide,
3-methoxy-5-(N,N-Hexamethylene)-amiloride,
3-methoxy-amiloride,
hexamethyleneimino-6-phenyl-2-pyrazinecarboximide,
N-amidino-3,5-diamino-6-phenyl-2-pyrazinecarboxamide,
1-naphthoylguanidine,
2-naphthoylguanidine,
N-(2-naphthoyl)-N'-phenylguanidine,
N,N'-bis(2-naphthoyl)guanidine,
N,N'-bis(1-naphthoyl)guanidine,
N,N'-bis(2-naphthoyl)-N''-phenylguanidine,
6-methoxy-2-naphthoylguanidine,
3-quinolinoylguanidine,
cinnamoylguanidine,
4-phenylbenzoylguanidine,
N-(cinnamoyl)-N'phenylguanidine,
(3-phenylpropanoyl)guanidine,
N,N'-bis-(cinnamoyl)-N''-phenylguanidine,
N-(3-phenylpropanoyl)-N'-phenylguanidine,
N,N'-bis(3phenylpropanoyl)-N''-phenylguanidine,
trans-3-furanacryoylguanidine,
N-(6-Hydroxy-2-naphthoyl)-N'-phenylguanidine,
(4-Phenoxybenzoyl)guanidine,

N,N'-Bis(amidino)naphthalene-2,6-dicarboxamide,
N''-Cinnamoyl-N,N'-diphenylguanidine,
(Phenylacetyl)guanidine,
N,N'-Bis(3-phenylpropanoyl)guanidine,
benzyoylguanidine,
(4-Chlorophenoxy-acetyl]guanidine,
N-benzoyl-N'-cinnamoylguanidine,
[(E)-3-(4-Dimethylaminophenyl)-2-methylacryloyl]guanidine,
(4-Chlorocinnamoyl)guanidine,
(4-Bromocinnamoyl)guanidine,
(4-Methoxycinnamoyl)guanidine,
(5-Phenyl-penta-2,4-dienoyl)guanidine,
(3-Bromocinnamoyl)guanidine,
(3-Methoxycinnamoyl)guanidine,
(3-Chlorocinnamoyl)guanidine,
(2-Chlorocinnamoyl)guanidine,
(2-Bromocinnamoyl)guanidine,
(2-Methoxycinnamoyl)guanidine,
(trans-2-Phenylcyclopropanecarbonyl)guanidine,
[3-(3-Pyridyl)acryloyl]guanidine,
(4-Hydroxycinnamoyl)guanidine,
(Quinoline-2-carbonyl)guanidine,
or pharmaceutically acceptable salts thereof.

162. (Original) A pharmaceutical composition comprising a compound according to claim 161, and optionally one or more pharmaceutical acceptable carriers or derivatives.
163. (Original) The pharmaceutical composition according to claim 162, further comprising one or more known antiviral compounds.

164. (Currently amended) The method according to any one of claims 4, 30, 56, 82, 100, 118 or 141 ~~4-6, 10, 11, 14, 17, 19, 21, 23, 25, 27, 29, 30 to 32, 35 to 37, 40, 43, 45, 47, 49, 51, 53, 55, 56 to 58, 61 to 63, 66, 69, 71, 73, 75, 77, 79, 81 to 85, 87 to 89, 92 to 94, 96, 97, 99, 100, 101 to 103, 105 to 108, 110 to 112, 114, 115, 117, 118, 120, 122-125, 127-129, 130-131, 133, 134, 136-144, 146-149, 151, 153, 155, or 156,~~ wherein said compound is selected from the antiviral compounds according to claim 161.
165. (Currently amended) The method according to any one of claims 4, 30 ~~29~~, 56, 82, 100, 118 or 141 ~~142~~, wherein said virus is Dengue virus and said compound is selected from the group consisting of cinnamoylguanidine, (2-chlorocinnamoyl)guanidine or trans -3-(1-naphthyl)acryloylguanidine.
166. (Original) The pharmaceutical composition according to claim 165, further comprising one or more known antiviral compounds.
167. (Currently amended) The method according to any one of claims 6 - 8, 12, 13, 16, 19, 21, 23, 25, 27, 29, 31, 32 to 34, 37 to 39, 42, 45, 47, 49, 51, 53, 55, 57, 58 to 60, 63 to 65, 68, 71, 73, 75, 77, 79, 81, 83 to 87, 89 to 92, 94 to 96, 98, 99, 101, 102, 103 to 105, 107 to 110, 112 to 114, 116, 117, 119, 120-122, 124-127, 129-131, 133-134, 136, 137, 139-147, 149-152, 154, 156, 158, or 159, wherein said compound is selected from the antiviral compounds according to claim 164.
168. (Currently amended) The method according to any one of claims 6, 31, 58, 84, 102 or 144, wherein said virus is Dengue virus and said compound is selected from the group consisting of cinnamoylguanidine, (2-chlorocinnamoyl)guanidine or trans -3-(1-naphthyl)acryloylguanidine.